Literature DB >> 12824532

Signaling to p53: the use of phospho-specific antibodies to probe for in vivo kinase activation.

Ashley L Craig1, Susan E Bray, Lee E Finlan, Neil M Kernohan, Ted R Hupp.   

Abstract

Phospho-specific antibody technology has been recently adopted to study p53 phosphorylation both in vivo and in vitro. We have developed and carefully characterized p53 phosphospecific reagents directed to major amino- and carboxy-terminal regulatory sites. The specificities of both polyclonal and monoclonal reagents targeting the same phospho-epitope are discussed. We have defined the major chemical binding determinants for specific monoclonal reagents by determining the relative contribution of charge and sequence to epitope recognition. Remarkably, we have found that the utility of these reagents in different assay systems is not universal and depends both on epitope conformation and affinity. This is reflected in the striking differences in their ability to detect endogenous p53 and recombinant protein. Therefore, we conclude that this novel class of reagents is not generally applicable, but that the utility of each reagent must be determined empirically.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12824532     DOI: 10.1385/1-59259-408-5:171

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  5 in total

1.  The MDM2 ubiquitination signal in the DNA-binding domain of p53 forms a docking site for calcium calmodulin kinase superfamily members.

Authors:  Ashley L Craig; Jennifer A Chrystal; Jennifer A Fraser; Nathalie Sphyris; Yao Lin; Ben J Harrison; Mary T Scott; Irena Dornreiter; Ted R Hupp
Journal:  Mol Cell Biol       Date:  2007-03-05       Impact factor: 4.272

2.  A novel p53 phosphorylation site within the MDM2 ubiquitination signal: I. phosphorylation at SER269 in vivo is linked to inactivation of p53 function.

Authors:  Jennifer A Fraser; Borivoj Vojtesek; Ted R Hupp
Journal:  J Biol Chem       Date:  2010-09-17       Impact factor: 5.157

Review 3.  Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.

Authors:  Michelle Martinez-Rivera; Zahid H Siddik
Journal:  Biochem Pharmacol       Date:  2011-12-26       Impact factor: 5.858

4.  A central role for CK1 in catalyzing phosphorylation of the p53 transactivation domain at serine 20 after HHV-6B viral infection.

Authors:  Nicola J MacLaine; Bodil Oster; Bettina Bundgaard; Jennifer A Fraser; Carolyn Buckner; Pedro A Lazo; David W Meek; Per Höllsberg; Ted R Hupp
Journal:  J Biol Chem       Date:  2008-07-31       Impact factor: 5.157

5.  The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway.

Authors:  Nicola J Maclaine; Ted R Hupp
Journal:  Aging (Albany NY)       Date:  2009-05-07       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.